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 Abstract 
Background: Measuring patient’s quality of life (QoL) in chronic diseases is very important 
to assess disease outcomes and impact of intervention. Inflammatory bowel disease (IBD) has 
a large impact on patient’s QoL. Disease activity has been suggested as an important 
indicator for QoL in patients with IBD. Limited studies regarding association between 
medication adherence and QoL in IBD patients are available worldwide and data was 
conflicting. Therefore, this study was performed to examine the association between disease 
activity, medication adherence and its impact on QoL among IBD in Palestine. Also, this 
study aimed to determine the QoL profile, medication adherence for IBD patients and stated 
the factors associated with QoL. 
Methods: A correlation cross-sectional study was conducted from July 2017 to February 
2018 at An-Najah National University Hospital, Nablus, Alia Governmental Hospital, 
Hebron and Dr. Khalil Suleiman Hospital, Jenin, Palestine. The disease specific tool 
inflammatory bowel disease questionnaire (IBDQ) was used to examine QoL. Medication 
adherence was measured using modified Morisky adherence scale8 (MMAS-8). The results 
were analyzed using Statistical Package for Social Sciences (SPSS) program version 20. 
Multiple linear regression analysis was performed to determine the most important variables 
related with QoL in IBD patients. 
 
 
 
 
X 
 
Results: One hundred and thirty two patients were involved in this study.  Of them, about 
58.3% are males with a mean ± SD for age of 34 ± 13 years ranged from 18-70 years. Active 
disease was reported in 81 participants (61.4%) in the previous 6 months. Using MMSA-8 
questionnaire, low adherence was reported in 39.4% of the participants. The reported QoL of 
this study was measured by using the average IBDQ scores, which was 150.72 ± 30.08 and 
this is indicated a low QoL among Palestinian IBD patients. Emotional and bowel domains 
are more disrupted than other domains. Active disease was the major significant factor 
associated with IBD patients QoL in its all dimensional score (P- value<0.001). No 
significant association was found between medication adherence and patients QoL.  
Diagnosis (Type of disease) didn’t affect any IBDQ dimensional score. Regression analysis 
revealed that: patients with remission (r
2
 = 0.436, p-value <0.001), with high educational 
status (r
2
 =0.035, p-value =0.009) and using Azathioprine drug (r2 =0.017, p- value =0.034) 
were independently associated with high QoL. 
Conclusions:  This study shows a low QoL among Palestinian IBD patients compared to 
other countries and identified a number of significant associated factors that should be 
considered when dealing with IBD. Results of the study may help healthcare providers to 
identify patients at risk of low QoL especially those in the relapse status and active 
symptoms. Attention should be provided by healthcare givers and strategy makers to increase 
knowledge about IBD, to improve IBD patient’s QoL and to identify the importance of 
treatment adherence. 
 
Keywords: Inflammatory Bowel disease, Inflammatory Bowel disease questionnaire, Active 
disease, Quality of Life, Palestine. 
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Introduction 
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1. Introduction 
1.1 Background  
 
1.1.1 Inflammatory bowel disease   
Inflammatory bowel disease (IBD) is an autoimmune disorder, defined as a chronic 
progressive relapsing inflammation of the intestinal mucosa (Hanauer 2006). It is comprised 
of Crohn’s disease (CD) and ulcerative colitis (UC).  IBDs commonly appear in young adults 
between the ages of fifteen and thirty, but it may occur at any age (Hanauer 2006, Baumgart 
and Carding 2007). 
Crohn's disease is a chronic IBD characterized by inflammation of the digestive 
or gastrointestinal (GI) tract. In fact, Crohn’s can affect any part of the GI tract, from the 
mouth to the anus, although the terminal part is most commonly involved (the ileum) where it 
joins the beginning of the large intestine (or colon). 
Ulcerative colitis is a chronic relapsing inflammatory disease of the colon. It affects the colon 
and rectum and typically involves only the innermost lining or mucosa, manifesting as 
continuous areas of inflammation and ulceration, with no segments of normal tissue (Colitis–
Pathophysiology 2003). 
The exact reason of IBD occurrence is not clear yet, it considered a result of complex 
relationship between genetic, infectious triggers, immune related and environmental factors 
like human gut microbiota, foods, smoke, chemical contamination that combine to contribute 
to progress of clinical CD (Gaya, Russell et al. 2006). It appears that immune system 
mistakenly attacks healthy bacteria in the GI tract then the chronic inflammation causes 
thickening of the intestinal wall, which triggers the symptoms (Khor, Gardet et al. 2011).  
Strong evidence suggests a genetic basis for IBD. Nearly 10 to 20% of IBD patients also have 
a family history of the disease, with the greater risk among first-degree relatives (mother, 
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father, sister, or brother). Relatives of affected individuals have at least a 10-fold increased 
risk for IBD (Orholm, Munkholm et al. 1991, Scott 2000). 
Inflammatory bowel disease is more common in developed countries (Bernstein, Fried et al. 
2010, Molodecky, Soon et al. 2012). However in recent years its rate in industrialized 
countries has been stabilized while the number of patients with CD is rising up in developing 
countries (Baumgart and Sandborn 2012) with  significant increase within Asian countries 
(Economou, Zambeli et al. 2009) . 
The diagnosis is made based on clinical features, endoscopic findings, histology, radiology 
and in some cases serology (Nikolaus and Schreiber 2007, Bernstein, Fried et al. 2010). 
Diagnosis is based on the presence of architectural distortion (e.g., trans-mural or superficial 
patchy granulomatous in filtration) and/or acute inflammatory cells with an inability to down 
regulate the inflammatory immune response once activated (Hanauer 2006, Bernstein, Fried 
et al. 2010). 
The predominant symptoms of IBD are diarrhea (with blood or/and mucus), GI bleeding, 
abdominal pain, weight loss, nausea and vomiting. Extra intestinal involvement includes skin 
lesions, arthritis, and iritis. Also, patients may develop abscesses and ulcers in the area of the 
anus in case of CD. Symptoms like joint pain, skin lesions, fatigue, and night sweats may also 
occur (FARMER 1974, Casati and Toner 2000, De Rooy, Toner et al. 2001). 
Use of effective treatment regimens aiming to maintain patients in remission is of great 
importance. In treatment approaches, they can be either "step-up," which starts with milder 
drugs first, or “top-down," which gives people stronger drugs earlier in the treatment process. 
Many pharmaceutical preparations can be used to treat IBD. Although medical treatment of 
IBD is individualized to each patient, anti-inflammatory drugs are often the first step in the 
treatment of IBD. They include drugs such as Aminosalicylates.  
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Aminosalicylates are one of the oldest drugs currently used in the treatment of IBD. 
Salazopyrin is the prototype drug in this family, however Mesalazine (5-aminosalicylic acid 
[5-ASA]) (Pentasa®) is the main Aminosalicylates used in IBD treatment today. These are 
safe drugs that can be administered orally or rectally to reduce inflammation localized to 
different regions of the GI. 5-ASA is highly effective in mild to moderate UC that is 
considered the drug of choice for approximately 90% of patients with UC at first diagnosis 
(Langholz, Munkholm et al. 1991). In CD,5-ASA is still a therapeutic option in conjunction 
with other therapies to adequately control inflammation with CD confined to the colon. 
However, current European Crohn’s and Colitis Organization (ECCO) discourages the use of 
5-ASA drugs in both ileac and colonic disease, even if mild (Travis, Stange et al. 2006). 
Aminosalicylates are associated with a number of side effects, including digestive distress 
and headache. 
Corticosteroids as anti-inflammatory are usually reserved for moderate to severe UC or CD 
patients that do not respond to other treatments. But it is associated with numerous side 
effects, including a puffy face, night sweats, excessive facial hair, insomnia and 
hyperactivity. More-serious side effects include high blood pressure, diabetes, osteoporosis, 
bone fractures, cataracts, glaucoma and increased chance of infection. They are not usually 
given for long term (Waljee, Wiitala et al. 2016). 
Immunomodulators suppress the immune response from releasing inflammation-inducing 
chemicals in the intestinal lining. The most widely used immunomodulator for treatment of 
IBD is Azathioprine (Imuran
®
). Close follow-up with doctor is required to check for side 
effects especially on the liver and pancreas. Additional side effects include lowered resistance 
to infection and a rare chance of developing cancers such as lymphoma and skin cancers. 
Severe leucopenia, thrombocytopenia, anemia including macrocytic anemia, and/or 
pancytopenia may occur in patients being treated with Azathioprine. Severe bone marrow 
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suppression may also occur depending on patients with intermediate thiopurine S-methyl 
transferase (TPMT).  
Cyclosporine is also considered an option but reserved for people who have not responded 
well to other medications. Its use is generally limited to UC with potential for serious side 
effects such as: kidney and liver damage, seizures and fatal infections and is not for long-term 
use. 
Tumor necrosis factor (TNF)-alpha inhibitors, or "biologics,” such as infliximab 
(Remicade
®
), adalimumab (Humira
®
) and golimumab (Simponi
®
) which work by 
neutralizing a protein produced by immune system. Methotrexate (Rheumatrex
®
) is 
sometimes used for people with CD who do not respond well to other medications. Care 
should be taken due to its side effects. 
Natalizumab (Tysabri
®
) and vedolizumab (Entyvio
®
) work by stopping certain immune cell 
molecules (integrins) from binding to other cells in the intestinal lining. Natalizumab is 
associated with a rare but serious risk of progressive multifocal leuko-encephalopathy. 
Vedolizumab was recently approved for CD; it works like Natalizumab but appears not to 
have a risk of brain infection. Ustekinumab (Stelara
®
) a drug used to treat psoriasis can be 
useful in treating Crohn’s. Also antibiotic can be used to reduce the amount of drainage and 
sometimes heal fistulas and abscesses in people with CD, commonly prescribed antibiotics 
are Metronidazole (Flagyl
®
) and Ciprofloxacin (Cipro
®
) (Mowat, Cole et al. 2011).  
Generally, diet and nutrition are one of the important interesting topics for patients with IBD. 
Patients try to use a dietary modification to manage their underlying symptoms; they may 
reduce or totally avoid nutritionally important foods, as this may place them at increased risk 
for developing nutritional deficiencies. A low residue diet is commonly recommended for 
IBD by health professionals (Brown, Rampertab et al. 2011). Pre-illness studies and 
intervention trials in IBD provide an evidence recommendation that a plant-based diet, 
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increased consumption of fruit and vegetables and reduced red meat intake could be optional 
to patients with IBD in remission (Hou, Abraham et al. 2011). Dietary risk factors for IBD 
development includes: an excessive consumption of sugar, animal fat and linoleic acid, while 
a citrus fruit and high fiber diet may play a protective role. 
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    1.1.2 Quality of life in IBD patients  
Health related Quality of Life (QoL) studies are an important aspect in clinical trials 
especially for chronic diseases. The concept measures the functional impact of a disease and 
its therapy on the patient’s daily life (Irvine 2008). As World Health Organization (WHO) 
defines health as not merely the absence of disease or infirmity, but a state of complete 
psychical, mental and social well-being(Organization 1995), QoL encompasses several 
dimensions in addition to physical functioning, including social, cognitive, emotional 
functioning, and participation in daily activities (Rubin, Hungin et al. 2004).  
All dimensions are related to each other, and they are affected by the patient's socio-
demographic and clinical characteristics (Wilson and Cleary 1995). 
In the past 10 years, there has been an increasing awareness of the importance of QoL issues 
related to IBD. Several studies indicate that QoL in IBD patients have been impaired in 
relative to healthy individual (Casellas, López-Vivancos et al. 2001, Nordin, Påhlman et al. 
2002). Patients with IBD need life-long medical treatments and GI specialist’s observation. 
Despite medical therapy reduces intestinal inflammation and ameliorates symptoms; curative 
therapy does not exist yet. Every drug has side effects that affect patient’s life one way or 
another. Also despite therapeutic advances, approximately 20% of patients will require 
intestinal re-sectional surgery during their lifetime (Colitis–Pathophysiology 2003, Cima and 
Pemberton 2005, Peyrin-Biroulet, Harmsen et al. 2012). 
 
Both UC and CD can be characterized as following a course of exacerbations followed by 
periods of remission; between 25% and 50% of patients will relapse within a year (Riley, 
Mani et al. 1990, Borley, Mortensen et al. 1997, Sewitch, Abrahamowicz et al. 2001, Husain 
and Triadafilopoulos 2004). All factors mentioned above  have significant physical and 
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psychosocial impact on the patient’s QoL (Ghosh and Mitchell 2007). The disease itself 
limits patient’s lifestyle and daily activities.  
Many socio-demographic variables such as gender, age, or educational level directly affect 
IBD patients QoL (Irvine, Feagan et al. 1994, Han, James et al. 1999, Hjortswang, Järnerot et 
al. 2003).  Clinical variables such as type of intervention (medical treatment or surgery), 
therapy effectiveness, the occurrence of extra intestinal symptoms, annual rate of flare-ups, 
their severity, or the need for hospitalization have an impact on IBD patients' QoL (Casellas, 
López-Vivancos et al. 2000).  
Generally in any chronic disease, treatment non-adherence is a common problem, averaging 
50% in developed countries and is even poorer in developing countries (Sabaté 2003).  
Association between medication adherence in IBD patients and their QoL is not clear and 
data available are differing from research to another.  
Adherence has been defined as  cooperation of the patients in taking prescribed drugs, which 
includes timing, dosage and frequency (San Roman, Bermejo et al. 2005). It can be measured 
using different tools that were tested in clinical and research settings (e.g., circulating drug or 
metabolites levels, pharmacy refill, patient questionnaires, interviews, and diaries),  no tool is 
considered a standard compared to others but self-report subjective measures appeared to be 
more reliable than the objective ones (Farmer 1999). One of the questionnaires that have been 
used to measure therapy adherence is the Modified Morisky Medication Adherence Scale 
(MMAS-8), a self-administered questionnaire, initially validated in patients on 
antihypertensive medications and then tested  and validated also in IBD (Krousel-Wood, 
Islam et al. 2009, Kane, Becker et al. 2012, Goodhand, Kamperidis et al. 2013).  
 
Non- adherence of IBD patients to their medication is a significant problem which may lead 
to several  adverse clinical outcomes including an increase in disease activity, relapse (Kane, 
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Huo et al. 2003, Khan, Abbas et al. 2012), loss of response to anti-TNF agents (van der Have, 
Oldenburg et al. 2016), increased health costs(Kane and Shaya 2008), disability and possibly 
poor QoL(Hommel, Davis et al. 2008) that lead to  higher morbidity and mortality (e.g., with 
colorectal cancer) . 
A comprehensive knowledge about how the disease process, symptoms, complications, 
management itself as well as medication adherence affect the patients’ QoL is needed. 
During assessment of IBD patients QoL several instruments that have generally reflected a 
physician’s perspective of disease activity were used. However QoL studies have suggested 
that functional status from the patient’s viewpoint may be more indicative of health care 
utilization than the physicians’ (Drossman, Patrick et al. 1989) and that patients are less likely 
to volunteer information regarding psychosocial impairment (Mitchell, Guyatt et al. 1988). 
Thus objections were raised to the inclusion of subjective instrument to assess patients QoL. 
Inflammatory Bowel Disease Questioner (IBDQ) a disease specific tool, the most common 
used questionnaire to assess the health related QoL in IBD patients worldwide. The IBDQ 
(Guyatt, Deyo et al. 1989, Irvine, Feagan et al. 1994) possesses both reliability and validity in 
several domains (digestive symptoms, emotional status, social function and systematic 
symptoms). 
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1.2 Statement of problem and study rational  
The incidence and prevalence of IBD are increasing with time and in different regions around 
the world, indicating its emergence as a global disease (Molodecky, Soon et al. 2012).The 
main goal of the treatment in any chronic disease such as IBD is to improve the patient’s 
symptoms and health related QoL. Many patients with IBD have concerns regarding  
symptoms, medication side effects, risk of cancer, and the need for surgery (Drossman, 
Patrick et al. 1989). All of these aspects can contribute to psychological distress and 
undermine QoL. Symptoms severity may hinder patients from enjoying their hobbies and 
affect their job performance. Health related QoL has received little scientific attention in 
gastroenterology, possibly because it’s difficult to conceptualize and measure. However, 
recent studies indicate that people are able to categorize certain dimensions such as systemic, 
bowel, social and emotional status. Many studies indicate a lack of communication between 
the patients and their physicians when it comes to QoL. 
Few studies on the association between drug adherence and health-related QoL in IBD 
patients are available and the data are conflicting(Chan, Chen et al. 2017).  
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1.3 Significance of the study 
It is important to have baseline data about IBD patients QoL and to use the quantitative 
assessment of health perception and ability to functioning the physical, social and emotional 
domains to evaluate the natural history of the disease, catalogue the needs of IBD patients, 
focus the direction of research and allocation of resources towards patient suffering and 
assess outcome in clinical studies.  
Measuring health related QoL, identifying the variables affecting it and evaluating whether 
health related QoL influences medication adherence and vice versa in IBD patients, is 
important to guide professionals towards intervention strategies implemented to improving 
patients QoL.To the best of our knowledge; this is the first study in the Palestinian West 
Bank to evaluate IBD patients QoL, the medications used and their medication adherence. 
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1.4 Objectives 
1.4.1 Main objectives 
The aims of this study were to evaluate our Palestinian IBD patients’ QoL and to assess the 
effect of socio-demographic, clinical variables and adherence to medication on the health 
related QoL and to identify its predictors. 
1.4.2 Specific objectives 
 To obtain information about personal experiences of patients with IBD and the 
impact of symptom flare-ups on patients’ QoL. 
 To identify the most commonly prescribed drug in the treatment of IBD both CD and 
UC in Palestinian patients. 
 To find the relationship between socio-demographic factors and the patient QoL 
 To find if smoking is considered as a predisposing factor for impaired QoL or no. 
 To find the effect of some clinical variables (disease duration, age at first diagnosis 
of the disease (age of onset), method of treatment (medical or surgical) on health 
related QoL.  
 To assess medication adherence among IBD Palestinian patients. 
 To find the relationship between medication adherence and patient QoL. 
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Chapter Two 
Literature Review 
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2. Literature Review 
Measuring patients QoL in chronic diseases is very important to assess disease outcomes and 
impact of its intervention (Moreno-Jiménez, Blanco et al. 2007). In this study we assessed 
Palestinian IBD patients QoL and established the relationship between socio-demographic, 
clinical factors with a health related QoL. This association has been investigated in other 
countries (Badia, Fernandez et al. 1995, Hjortswang, Järnerot et al. 2003, Han, McColl et al. 
2005). Several studies have indicated the importance of age, educational level (Drossman, 
Leserman et al. 1991, Badia, Fernandez et al. 1995, Hjortswang, Järnerot et al. 2003) or sex 
with regard to QoL in IBD processes. The duration of IBD, the effects of treatments, and the 
consequences of its complications also affect the daily lives of these patients and impair their 
QoL (Drossman, Leserman et al. 1991). A study conducted in Saudi Arabia showed that 
patients aged 20 years to less than 30 years and patients with higher education levels had 
significantly better social QoL scores, also the longer disease duration (5 years or more) was 
associated with significantly lower systemic QoL scores than shorter duration (Mahalli and 
Alharthi 2017). 
 Also a study conducted by Blanco, Moreno-Jimenez et al. 2005found that men showed 
higher QoL scores in systemic, bowel, emotional and social symptoms and global IBDQ, and 
the differences between males and females were significant (Blanco, Moreno-Jimenez et al. 
2005). 
Many clinical variables such as type of treatment (medical treatment or surgery), occurrence 
of extra intestinal symptoms, presence of flare-ups and symptoms, their severity or the need 
for hospitalization have a great impact on IBD patients’ QoL (Casellas, López-Vivancos et al. 
2000, Blanco, Moreno-Jimenez et al. 2005). Moreover, Blanco et al. (Blanco, Moreno-
Jimenez et al. 2005) showed patients undergoing surgery had lower QoL scores in 
comparison to those who received medical treatment only.  
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As the disease activity is one of the most important predictors for decreased QoL (Larsson, 
Lööf et al. 2008). Active disease has been found to contribute to poor QoL for IBD patients 
(Blondel-Kucharski, Chircop et al. 2001, Casellas, López-Vivancos et al. 2002, Janke, Raible 
et al. 2004, Saibeni, Cortinovis et al. 2004, Casellas, Arenas et al. 2005). IBD patients in 
remission scored significantly higher QoL scores for all domains using Short Form-36 (SF-
36)(Zhou, Ren et al. 2010). Usually the patients who had relapse had an increased symptoms 
severity , stress, anxiety and lower QoL score compared to those who had inactive disease 
(Graff, Walker et al. 2006). In a Spanish study, they found that as disease severity worsened, 
a corresponding worsening in QoL occurs, regardless of disease subtype either CD or UC 
(Casellas, Arenas et al. 2005). 
Symptoms severity hindered IBD patients from enjoying their hobbies and affected their job 
performance. A survey  conducted by De Rooy et al., for IBD outpatients found that concerns 
regarding  loss of bowel control, producing unpleasant odors, achieving their full potential in 
the workplace, feeling dirty or smelly, and issues with sexual problems, ranked highly for 
both UC and CD (De Rooy, Toner et al. 2001). While there is some controversy in the field 
of evidence, Many studies indicate that patients with CD are more affected by their disease in 
terms of QoL than are patients with UC (Drossman, Leserman et al. 1991, Farmer, Easley et 
al. 1991, Irvine 1997). 
This study assessed patients QoL using IBDQ as a subjective tool to indicate the impact of 
disease on patient's QoL. The IBDQ total score in health related QoL assessment studies in 
countries such as Netherlands, England, and Greece and Saudi Arabia has been calculated (de 
Boer, Wijker et al. 1995, Han, McColl et al. 1998, Pallis, Vlachonikolis et al. 2002). In some 
studies, IBD had more impact on patients’ social and systemic symptoms when compared to 
the emotional and bowel symptoms (de Boer, Wijker et al. 1995, Han, McColl et al. 1998, 
Pallis, Vlachonikolis et al. 2002). 
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The link between IBD and smoking was reported in many studies. Smoking is known to 
affect disease activity in IBD (Russel, Nieman et al. 1996), in a cross sectional study 
conducted by Russel et.al., on 1105 patients with IBD, they concluded  a relationship 
between smoking and patients QoL in both UC and CD as smoking females had a lower QoL 
than non-smoking females in all  dimensions of the IBDQ. In this study, we tried to find if 
smoking is considered as a predisposing factor for impaired QoL or not (Russel, Nieman et 
al. 1996). 
Dietary factors in IBD development seem to play an underestimated role in the clinical course 
of the disease. On the other hand, data about food and IBD is not clear yet. Appropriate 
nutrition in both disease period (relapse and remission) may help prolonging remissions and 
thus improve the QoL for patients. Up to 71% of patients with IBD believe that diet affects 
their clinical course of disease and symptoms, with 90% of CD patients and 71% of UC 
patients employing diet restriction while in remission (Owczarek, Rodacki et al. 2016, Holt, 
Strauss et al. 2017). In a case-control study conducted by Guerreiro et.al., a significantly 
lower mean daily intakes of several dietary groups were found in IBD patients  due  to 
patients  exclusion of dairy products, vegetables and fruit (Guerreiro, Cravo et al. 2007). 
Appropriate medication adherence is an important issue for successful IBD therapy.  It seems 
reasonable that a good adherence to therapy results in a better QoL. But in IBD patient’s data 
regarding association between drug adherence and health-related QoL in IBD patients was 
limited and controversial. In this study, we will try to evaluate whether health related QoL 
influences medication adherence in IBD patients and vice versa or not. In Hommel et al  
(Hommel, Davis et al. 2008) study the relationship between medication adherence and QoL 
in 36 young people with IBD was significant. Non-adherence to 6-mercaptopurine 
/Azathioprine was significantly associated with lower physical health QoL in patients. On the 
other hand, a study conducted by Horvath et al. (Horváth, Farkas et al. 2012)enrolled 592 
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IBD patients to evaluate whether QoL influences medication adherence and vice versa using 
Short Form-36 (SF-36) questionnaire and a medication adherence report scale. Their study 
concluded that no association between the sums of health related QoL and different sub-
scores and non-adherence. They demonstrated that IBD is related to low QoL, which is not 
affected by drug therapy. Forgetting to take the medication' was the main reason for non-
adherence in 67.6% of the cases. Medication adherence was significantly higher among non-
smoker patients, and in the case of immunomodulator therapy. In some studies, the term of 
disability which seems to be more objective in measuring the effects of non-adherence on  
IBD patients than QoL, was found to be significantly higher in non-adherers than adherent 
patients (Horváth, Farkas et al. 2012). 
In Jackson et.al., review (Jackson, Clatworthy et al. 2010) of 17 studies with 4,322 adult IBD 
subjects found that oral medications non-adherence in IBD ranging from 7% to 72%. But the 
rate in Asian IBD patients ranged between 20% and 30% (Kawakami, Tanaka et al. 2013).  
Many studies concluded that adherence rate with biological therapy is higher than other 
medications (Selinger, Robinson et al. 2011, Lopez, Billioud et al. 2013).  
Poor medication adherence has several clinical  outcomes, for example Kane, Huo et al 
demonstrated that non-adherent IBD patients had more than a fivefold greater risk of 
recurrence than adherent patients (Kane, Huo et al. 2003). Also non-adherence to anti-TNF 
therapy may result in immunogenicity thus decrease response to treatment.  
In a study conducted by Van der Have et al. on 128 IBD patients who were on either 
infliximab or adalimumab, adherence was negatively associated with loss of response to anti-
TNF agent (van der Have, Oldenburg et al. 2016). 
A study conducted in 2017 (Bucci, Zingone et al. 2017) to assess factors predicting adherence 
to therapy in Italian IBD, 151 patients filled MMAS-8 questionnaire. Almost 30% of IBD 
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patients reported low compliance to therapy. According to the scale, they showed a 62.5% 
medium to high adherence to oral 5-ASA, a 72% medium to high adherence to 
Immunomodulators, and a 60% medium to high adherence to oral steroids and 94.9% 
adherence to biologics. Younger patients tend to be less compliant to their therapy. The main 
reasons for the low adherence to therapy were the “hassle of sticking to the medication plan” 
and “their feeling better”. 
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3. Methodology 
This section describes the population and the subjects of the study, sample size, data 
collection instrument, and data analysis method.  
3.1 Study design 
This cross-sectional study was conducted by using standardized and validated assessment 
tools with IBD patients from July 2017 to February 2018. 
3.2 Study setting 
This study was conducted in Al-Najah National University hospital (Dr. Qusay clinic) the 
main referral hospitals for the northern Palestine, Nablus, Dr. Khalil Suleiman Hospital, Jenin 
and Hebron governmental hospital; Hebron. These hospitals serve as the major referral 
hospitals for the northern and southern districts of West Bank-Palestine and receive most 
cases of IBD patients from all northern and southern West Bank districts. 
3.3 Study population 
The medical records of all hospitals in 2017 showed that the number of IBD patients in 
hospitals was 200 patients during the study period (the numbers were taken from the hospital 
medical records and medication sheets). Each studied hospital gave us a list with the names 
of IBD patients in order to assess their comfort for this study. 
3.4 Sampling procedure and sample size calculation 
The Raosoft sample size calculator (an automated software program: 
 http://www.raosoft.com/samplesize.html) was used for sample size calculation. We used a 
5% margin of error at a 95% confidence interval as recommended; the required sample size 
was calculated to be 132 patients. Convenience sampling was used to recruit participants. 
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3.5 Inclusion and exclusion criteria 
Patients aged 18 years and above who had UC or CD and were under the treatment for the 
disease, and who agreed to be participants in this study were included. Pregnant women were 
excluded. 
3.6 Data collection 
Data collection form (Appendix 1) was a questionnaire prepared after literature review of 
previous studies. Standard demographic questions were used to assess age, sex, and other 
background and clinical variables: disease duration, age at first diagnosis of the disease (age 
of onset), and disease activity (remission or relapse), method of treatment (medical or 
surgical), etc. Disease activity was determined based on patient report of symptom 
persistence for the previous 6 months, using a 6-level response format from (a – f). Active 
disease was defined as experiencing symptoms constantly to occasionally in the last six 
months and represented by (one of responses a– d), and inactive disease was defined as 
experiencing infrequent symptoms or feeling well (responses e or f).  
Modified Morisky Medication Adherence Scale (MMAS-8), a self-administered 
questionnaire, initially validated in patients on antihypertensive medications and then tested 
and in IBD patients (Krousel-Wood, Islam et al. 2009, Kane, Becker et al. 2012, Goodhand, 
Kamperidis et al. 2013). In 2011, Trindade et al. validated this questionnaire in IBD, 
concluding that it could identify patients with poor adherence better than physicians 
(Trindade, Ehrlich et al. 2011) . Response categories are dichotomous with yes/no for the first 
7 items and a 5-point Likert response for the last item. The scale is scored by assigning a 
single point to each question answered “no” in questions 1-4 and 6-7. A point is given in 
question 5 for an answer of “yes.” 
Health related QoL was assessed by using a disease specific questionnaire IBDQ. IBDQ was 
validated and translated into Arabic language previously. IBDQ have an adequate validity 
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and reliability in different languages and cultures.  We obtained the Arabic-translated version 
form McMaster University (Guyatt, Mitchell et al. 1989).The IBDQ contains 32 questions 
that are classified into four main domains: bowel symptoms (10 questions), social impairment 
(5 questions), emotional function (12 questions) and systemic symptoms (5 questions) (Irvine 
1993). The options for each question are graded from 1 to 7, where 1 indicates the worst 
symptoms and 7as the best symptoms. The total score ranges from 32 to 224 the higher score 
indicates a better QoL. 
Academic experts in clinical pharmacists and academic researcher in statistical analysis 
reviewed and evaluated measurement items for content validity and clinical accuracy. Data 
collection forms were completed by interviewing participants. 
3.7 Statistical analysis  
All data was coded, entered and analyzed using SPSS windows version 20. Descriptive 
statistics were carried out for all variables. Mean ± standard deviation or median (Q1-Q3) 
were computed for domains. Frequencies (percentages) were calculated for socio-
demographic variables. Categorical variables were compared using Chi-square. Independent 
student t-test or Mann Whitney tests used to compare means for two groups. One way 
ANOVA was used to compare groups of more than two; Kolmogorov–Smirnov test was used 
for normality. The comparison between UC and CD was made by chi-squared test and t-test. 
The comparison between the two groups depended on the total of the IBDQ scores and the 
four domains of the IBDQ where a P-value ≤ 0.05 was considered as significant result. 
Multiple linear regression tests were used to examine the factors affecting IBDQ score. 
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3.8 Ethical consideration  
Approval from Research Ethical Committee (REC) at Al-Quds University (Appendix 2) and 
Palestinian Ministry of Health was taken before the study initiation (Appendix 3). All patients 
were interviewed after receiving consent form that confirms their willing to participate 
(Appendix 4). 
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4. Results 
4.1 Socio-demographic and clinical characteristics of the patients 
One hundred and thirty-two patients were interviewed during the study period in three 
different hospitals; 78 (59%) patients from Al-Najah National University Hospital -the major 
center in southern Palestine-, Nablus, 35(27%) patients from Alia Governmental Hospital, 
Hebron and 19 (14%) patients from Dr. Khalil Suleiman Hospital, Jenin (Figure 4.1). 
 
         
Figure 4.1: Number of participants interviewed from hospitals included in the study 
 
 
 
Seventy-seven participants (58.3%) were males (Figure 4.2). Mean ± standard division of the 
sample age equals to 34 ± 13 years ranged from 18-70 years.  
Al-Najah 
University 
Hospital78(59%) 
Alia 
Governmental 
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Figure4.2: Gender distribution of patients participating in the study 
 
Eighty-six (65.2%) participants were married. More than 52% of the participants were 
employed and 56 (42.4%) participants with a moderate monthly income level. 40% of the 
patients had a university educational level.  51.5% of patients were diagnosed at the age 
between fifteen to thirty years. The duration of disease was divided into two groups: a group 
included those who had the disease for less than 5 years, the other group who had the disease 
for 5 years and more. More than 32% of participants were smokers. 18.9% of participants had 
a first-degree relative (mother, father, sister, or brother) diagnosed with IBD. 29.5% had a 
stress related condition before a short time of disease diagnosis. All patients received medical 
treatment during study period. Sixteen participants (12.9%) exposed to surgical treatment 
during the disease life (Table 4.1). 
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Table4.1: Socio-demographic and clinical data of the study participants 
 
Socio-demographic factors Frequency  Percentages(N =132) 
Marital status 
Single, never married 
 
46 34.8% 
Married or domestic partnership 
 
86 65.2% 
Current status 
Student 22 16.7% 
Employed 
 
69 52.3% 
Unemployed 
 
41 31.1% 
Income 
Less than ₪3000 
 
48 36.4% 
₪3000-₪4000 
 
56 42.4% 
More than ₪4000 
 
28 21.2% 
Level of 
education 
University or college or equivalent 
 
54 40.9% 
Intermediate between secondary level and 
University 
15 11.4% 
Secondary school 
 
40 30.3% 
Primary school only (or less) 
 
23 17.4% 
Age at 1
st
  
diagnosis 
Less than 15 years 
 
14 10.6% 
15 to 30 years 
 
68 51.5% 
More than 30 years 
 
50 37.9% 
Disease duration 
Less than 5 years 
 
83 62.9% 
5 years and more  49 37.1% 
First degree 
relative 
No 
 
107 81.1% 
Yes 
 
25 18.9% 
Stress related 
condition 
No 
 
93 70.5% 
Yes 
 
39 29.5% 
Smoking habits 
No 
 
89 67.4% 
Yes 
 
43 32.6% 
Method of 
Treatment 
Drugs 
 
115 87.1% 
Both surgical and drugs 
 
16 12.9% 
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6.2Type of food and dietary restriction 
During the patient’s interview, around 69% of them were found to include fruits and 
vegetables in their diet and 31% relied on fast food (Figure 4.3). 
 
 
 
 
 
 
Figure 4.3: Type of food that patients generally eat 
 
Ninety patients (68%) avoided certain types of foods such as milk, cereals and others (figure 
4.4). 
                           
Figure4.4: Percentage of dietary restriction among IBD patients 
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4.3. Medications prescribed for IBD patients  
4.3.1. Medications prescribed to treat IBD  
Several types of medications have been prescribed. The most common medications 
prescribed were Azathioprine (Imuran
®
) in 96 patients (72.7%), 5-ASA (Pentasa
®
) in 68.2% 
of patients and Adalimumab (Humira
®
) in 26.5% of patients as shown in Figure 4.5. 
 
Figure4.5: Medications prescribed to treat IBD 
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4.3.2 Antibiotic prescribed to IBD patients. 
One hundred and seventeen patients (88.6%) were not prescribed antibiotic during the study 
period, others were prescribed Ciprofloxacin, Metronidazole or both with the following 
percentages 1.5%, 6.1% and 3.8% respectively as shown in table 4.2. 
Table 4.2: Antibiotic prescribed to IBD patients 
Antibiotic usage 
 
Frequency Percentages 
Patients were not prescribed Antibiotic 
 
117 88.6% 
Patients were prescribed Ciprofloxacin 
 
2 1.5% 
Patients were prescribed Metronidazole 
 
8 6.1% 
Patients were prescribed Both (Ciprofloxacin and 
Metronidazole) 
 
5 3.8% 
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4.4 Assessment of disease activity status in IBD patients: 
Active disease or relapse was reported in 81 participants (61.4%) in the previous 6 months. 
 
 
 
 
 
 
Figure 4.5: Disease activity measurement 
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4.5 Assessment of Medication adherence among IBD patients: 
Based on MMAS-8, 52 (39.4%) of patients had a low adherence, 54 (40.9%) had a medium 
adherence and 26 (19.7%) had a high medication adherence. The average adherence score is 
5.70 ±1.86 for the study sample generally indicates low rate of adherence among Palestinian 
IBD patients. 
 
 
Figure 4.6: Medication adherence among IBD patients. 
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4.6 Type of Disease  
The majority of patients were diagnosed with CD 83(62.9%) with a mean age of (32.73 
±12.71), while others with UC 49(37.1%) with higher mean age (34.94±12.69) as shown in 
(Figure 4.7). 
 
                   
  Figure 4.7: Type of disease according to physician’s data. 
 
Of males, fifty two participants were diagnosed with CD (67.5%), others with UC (32.5%), 
no significant difference between CD and UC according to their gender. In both diseases the 
majority of patients are those of highly educated level and diagnosed between (15 -30) years. 
As forty three participants were smokers, nearly 70% of them were diagnosed with CD, 
others with UC; however the difference was not significant. 
According to clinical characteristics of the participants, around 94% of patients who undergo 
a surgery during their disease life were CD patients, while others were UC patients and the 
difference was significant (P-value=0.017). Drugs prescribed to treat both diseases are 
similar, on the other hand the use of Pentasa
®
 and Remicade
®
 had a statistically significant 
difference between the two groups (CD and UC)as P-value = (0.003, 0.006); respectively. As 
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Active disease was reported in 81 participants (61.4%) in the previous 6 months, 60.5% of 
them were CD while others were UC patients (39.5%). 
The majority of CD patients showed a medium adherence to their drug medication (42.16%), 
while the majority of UC (42.85%) showed low adherence to their medication. All data was 
shown in Table 4.3. 
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Table 4.3: Demographics according to the type of disease (CD vs. UC) identified, P-value. 
Socio- demographic  
factor  
Sub classification CD UC P- value 
Frequency 
(%) 
Frequency 
(%) 
Gender Male 
 
52(67.5%) 25(32.5%) 
0.190 
Female 
 
31(56.4%) 24(43.6%) 
Level of education University or college  
 
35(64.8%) 19(35.2%) 
0.723 
Intermediate school  
 
11(73.3%) 4(26.7%) 
Secondary school 
 
23(57.5%) 17(42.5%) 
Primary school or less 
 
14(60.9%) 9(39.1%) 
Age_1st_diagnosis Less than 15 10 (71.4%) 4(28.6%) 
0.569 15_30 40 (58.8%) 28(41.2%) 
More than 30 33 (66.0%) 17(34.0%) 
Stress related 
condition 
No 56 (60.2%) 37 (39.8%) 
0.328 
Yes 27(69.2%) 12 (30.8%) 
First degree 
relatives 
No 70(65.4%) 37 (34.6%) 
0.211 
Yes 13(52.0%) 12 (48.0%) 
Smoking habit  No 53 (59.6%) 36 (40.4%) 
0.255 
Yes 30(69.8%) 13(30.2%) 
Method of 
treatment 
Drugs 67 (58.3%) 48(41.7%) 
0.017 
Surgical and drugs 16 (94.1%) 1(6.3%) 
Prednisone users  15(60.0%) 10(40.0%) 0.741 
Imuran  users  64(66.7%) 32(33.3%) 
0.141 
Humira  users 22 (62.9%) 13(37.1%) 0.998 
Pentasa  users 49 (54.4%) 41 (45.6%) 0.003
*
 
Remicade users 15 (93.8%) 1 (6.3%) 0.006
*
 
Disease  activity  Active disease 49 (60.5%) 32 (39.5%) 
0.475 
Inactive disease 34 (66.7%) 17 (33.3%) 
Medication 
adherence  
High adherence 17 (65.4%) 9 (34.6%) 
0.821 Medium adherence 35 (64.8%) 19(35.2%) 
Low adherence 31 (59.6%) 21(40.4%) 
*P value ≤0.05 
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4.7 Assessment of health related QoL in IBD patients 
The mean score of IBDQ in total sample of patients was (150.72 ± 30.08) ranged from 48.96 
to 208.96. The mean total score is less than 157 and represents low QoL in Palestinian IBD 
patients (Irvine 1993). 
In the comparison of the four domains of the IBDQ, it was found that social and systemic 
domains had higher score than other domains with mean per item± SD equal to (24.75±6.6),  
( 23.7±6.45), respectively. 
 
    Table 4.4: Assessment of health related QoL in IBD patients (N=132). 
IBDQ domains Range IBDQ Scores± SD Median 
Bowel functioning 
 
10–70 46.1±12.2 47 
Emotional functioning 
 
12–84 54.48±13.56 58 
Systemic domain 
 
5–35 23.7±6.45 26 
Social domain 5–35 
 
24.75±6.6 25 
Total IBDQ score 32–224 150.72±30.08 151 
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4.8. Relationships between IBD patients QoL with other independent variables 
4.8.1. Association of QoL with socio-demographic and clinical variables of the patients 
Total IBDQ score was not affected by socio-demographic factors such as: gender, material 
status, occupation, level of education and smoking, however, the disease activity status had a 
statistically significant effect at the level of significant α≤0.05, the mean IBDQ scores and all 
its domains showed that patients in remission (inactive disease stage) had better QoL scores 
than those in relapse (P value =0.000). In the comparison of IBDQ scores between CD and 
UC no significant difference had been detected (P value=0.882). 
Clinical variables such as: disease duration, age at disease onset  and treatment options didn’t 
affect any IBDQ dimensional score. The mean bowel domain of IBDQ scores showed a 
significance differences depending on the presence of first degree relatives in family while 
the mean systematic domain had a nearly significant difference among Adalimumab users 
and non-users (P-value=0.047) as shown in Table 4.5. 
Although there is no significance correlation at the level of significant α≤0.05 between age 
and the IBDQ (R= 0.065, P-value= 0.232), there is a positive correlation between age and 
emotional domain (R= 0. 0.174, P-value= 0. 0.24) as shown in Table 4.6. 
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Table 4.5: Association between QoL and socio-demographic and clinical variables of the 
patients. 
Socio-
demographic 
and clinical 
variables 
Sub-classification 
Systemic 
Mean rank 
per item 
Social 
Mean 
rank per 
item 
Bowel 
Mean rank 
per item 
Emotional 
Mean rank 
per item 
IBDQ 
Mean ± 
SD 
Type of disease 
 
Crohn's disease 
4.80±1.25 4.95±1.27 4.64 ± 1.21 4.50±1.12 4.71±0.93 
 
Ulcerative colitis 
4.64±1.37 4.94±1.40 4.57 ± 1.24 4.59±1.15 4.70±0.97 
P- value 0.307 0.860 0.818 0.882 0.943 
Gender 
 
Male 
4.80±1.22 5.01±1.14 4.57 ± 1.13 4.51±1.07 4.72±0.81 
 
Female 
4.65±1.38 4.85±1.54 4.6 ± 1.33 4.57±1.22 4.68±1.11 
P- value 0.299 0.795 0.921 0.409 0.998 
Marital Status 
 
Single 
4.73±1.21 4.99±0.22 4.52 ± 1.28 4.34±1.09 4.72±0.12 
 
Married 
4.74±1.34 4.92±1.63 4.66 ± 1.19 4.64±1.14 4.70±1.17 
P- value 0.881 0.651 0.647 0.442 0.783 
Current Status 
 
Student 
4.52±1.21 4.99±0.22 4.47 ± 1.22 4.20±1.03 4.70±0.02 
 
Employed 
4.82±1.28 5.01±1.32 4.72 ± 1.05 4.66±1.05 4.75±0.91 
 
Unemployed 
4.70±1.36 4.80±1.63 4.51 ± 1.46 4.50±1.46 4.63±1.22 
P- value 0.152 0.600 0.400 0.387 0.689 
Income 
 
Low 
4.40±1.40 4.67±1.35 4.39 ± 1.37 4.17±1.27 4.52±1.02 
 
Moderate 
4.91±1.09 4.99±1.35 4.63 ± 1.14 4.71±0.96 4.77±0.90 
 
High 
4.95±1.39 5.31±1.12 4.97 ± 1.02 4.81±1.06 4.90±0.85 
P- value 0.347 0.336 0.993 0.464 0.632 
Level of  
education 
University or 
college 
4.80±1.27 5.22±1.10 4.88 ± 1.04 4.79±1.05 4.92±0.73 
Intermediate  4.76±1.46 4.82±1.49 4.80 ± 1.43 4.63±1.29 4.72±1.15 
 
Secondary school 
4.71±1.17 4.73±1.36 4.36 ± 1.24 4.21±1.10 4.50±0.97 
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Primary school 
only (or less) 
4.62±1.50 4.75±1.54 4.30  ±1.32 4.42±1.15 4.56±1.13 
P- value 0.215 0.586 0.231 0.155 0.193 
History of 
smoking 
 
No 
4.80±1.28 5.00±1.32 4.69 ± 1.27 4.61±1.19 4.77±0.92 
 
Yes 
4.62±1.31 4.82±1.32 4.46 ± 1.09 4.39±0.99 4.58±0.94 
P- value 0.079 0.613 0.578 0.108 0.704 
Stress related 
condition 
 
No 
4.75±1.25 4.99±1.34 4.58 ± 1.22 4.59±1.09 4.77±0.94 
 
Yes 
4.70±1.39 4.83±1.26 4.70 ± 1.22 4.42±1.22 4.56±0.98 
P- value 0.114 0.567 0.754 0.290 0.400 
1
st
 degree 
relatives 
 
No 
4.73±1.28 4.94±1.33 4.64±1.23٭ 4.50±1.12 4.69±0.91 
 
Yes 
4.62±1.31 4.99±1.30 4.49 ± 1.17 4.71±1.19 4.76±0.69 
P- value 0.320 0.099 0.031* 0.486 0.228 
Method of 
Treatment 
 
Drugs 
4.71±1.32 4.96±1.37 4.63 ± 1.21 4.59±1.14 4.72±0.99 
 
Both surgical and 
drugs 
4.87±1.08 4.82±0.92 4.41  ±1.34 4.14±0.99 4.58±0.54 
P- value 0.676 0.769 0.058 0.774 0.749 
Drugs used to 
treat IBD 
 
Prednison
e 
No 
5.02±1.04 
 
5.20±1.05 4.85 ± 1.00 4.75±0.96 4.89±0.73 
Yes 
3.54±1.56 
 
3.85±1.75 3.56 ± 1.54 3.64±1.37 3.91±1.28 
P- valve 0.889 0.899 0.702 0.493 0.762 
Imuran 
No 
4.67±1.52 
 
4.70±1.61 4.73±  1.31 4.65±1.34 4.57±1.25 
Yes 
4.76±1.20 
 
5.04±1.18 4.57 ± 1.18 4.49±1.04 4.76±0.80 
P- value 0.262 0.887 0.860 0.615 0.696 
Humira 
No 
4.93±1.15 
 
5.11±1.25 4.73  ±1.11 4.70±1.00 4.82±0.85 
Yes 
4.19±1.53 
 
4.49±1.40 4.29 ± 1.45 4.08±1.33 4.38±1.10 
P-value  0.047* 0.074 0.849 0.513 0.065 
Pentasa 
No 
4.62±1.34 
 
4.98±1.16 4.65 ± 1.35 4.36±1.16 4.72±0.94 
Yes 4.79±1.27 
4.93±1.39 
 
4.60 ± 1.16 4.62±1.11 4.70±0.93 
P-value  0.423 0.062 0.229 0.575 0.217 
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Methotrex
ate 
No 4.73±1.30 
4.95±1.33 
 
4.61 ± 1.22 4.52± 1.13 4.72±0.94 
Yes 5.20±0.28 
4.95±0.00 
 
4.90 ± 0.85 5.25 ±0.59 4.70±0.93 
P-value 0.874 0.716 0.709 0.120 0.687 
Remicade 
No 4.74±1.32 
4.93±1.34 
 
3.63 ± 1.21 4.55± 1.16 4.71±0.95 
 
Yes 
4.69±1.12 5.06±1.15 4.49 ± 1.29 4.46±  0.89 4.71±0.00 
P-value 0.420 0.642 0.440 0.852 0.671 
Salazopyri
n 
No 4.74±1.29 
4.95±1.32 
 
4.62±  1.22 4.54±  1.13 4.70±0.98 
Yes 4.80±0.00 5.4±0.00 4.30±  0.00 4.42±  0.00 4.78±0.58 
P-value 0.050* 0.170 0.661 0.687 0.331 
Vedolizu
mab 
No 
4.73±1.29 
 
4.95±1.32 4.61±1.22 4..53±1.13 4.71±0.94 
Yes 
5.2±0.00 
 
4.95±0.00 5.50±0.00 5.50±0.00 4.59±0.00 
P-value 0.941 0.890 0.551 0.341 0.998 
Antibiotic used 
No 
 
4.84±1.16 5.08±1.17 4.73 ± 1.10 4.64±1.00 4.80±0.82 
Ciprofloxacin 
 
4.80±0.57 4.70±0.71 4.35 ± 0.35 4.75±1.06 4.63±0.53 
Metronidazole 
 
4.46±2.17 4.24±1.90 4.23 ± 1.98 4.17±1.75 4.34±1.29 
Both 
Ciprofloxacin & 
Metronidazole 
2.60±1.21 2.94±1.90 2.68 ± 1.08 5.65±1.45 3.04±1.58 
P-value 0.779 0.790 0.622 0.991 0.836 
 
Type of food 
Fast food 
 
4.77±1.20 5.07±0.90 4.83±  1.08 4.60±1.10 4.77±0.68 
Fruits and 
vegetables 
 
4.72±1.34 4.89±1.47 4.52 ± 1.27 4.51±1.14 4.68±1.04 
P-value 0.318 0.530 0.542 0.318 0.474 
Dietary 
restriction 
Yes 
 
5.04±1.24 4.86±1.31 4.45±  1.24 4.48±1.14 4.62±0.92 
No 
 
4.62±1.29 5.19±1.27 4.99  ±1.08 4.72±1.05 4.94±0.92 
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P-value 0.422 0.317 0.763 0.267 0.568 
Disease activity  
Active Disease 
 
4.22±1.33 4.45±1.37 4.11±1.24 4.09±1.15 4.31±0.94 
Inactive disease 
 
5.55±0.65 5.73±0.69 5.40±0.60 5.24±0.63 5.32±0.53 
P-value 0.000* 0.000* 0.000* 0.000* 0.000* 
*P value ≤0.05 
 
 
 
 
Table 4.6: Correlation between age and IBDQ scores using Pearson correlation coefficient 
QoL scores 
Age  
 
R 
 
Sig 
Bowel domain 
 
0.085 0.169 
Emotional domain 
 
0.174 0.024 * 
Systemic domain 
 
0.042 0.317 
 
Social domain 
0.027 0.380 
IBDQ 
0.065 0.232 
*P value ≤0.05 
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4.8.2 Association of QoL with medication adherence  
There was no association between the sum of health related QoL and different sub-scores of 
health related QoL and non-adherence. 
Table 4.7: Association between medication adherence and patients QoL 
 Medication adherence Mean± SD P-value 
Bowl domain 
high adherence 
 
4.4962± 1.39871 
0.749 
 
 
medium adherence 
 
4.5815± 1.29339 
low adherence 
 
4.7078± 1.03862 
Emotion domain 
high adherence 
 
4.4199± 1.33051 
0.818 
 
 
medium adherence 
 
4.5355± 1.14291 
low adherence 
 
4.5929± 1.01790 
Systemic domain 
high adherence 
 
4.4769± 1.59105 
0.101 
 
 
medium adherence 
 
4.5815± 1.38142 
low adherence 
 
5.0353± 0.94124 
Social domain 
high adherence 
 
4.6197± 1.75347 
0.355 
 
 
medium adherence 
 
4.9864± 1.26827 
low adherence 
 
5.0669± 1.09381 
IBDQ 
high adherence 
 
4.4042± 1.16688 
0.149 
 
medium adherence 
 
4.7172± 0.95365 
low adherence 
 
4.8450± 0.77261 
*P value ≤0.05 
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4.9 Predictors of QoL domains 
Regression analysis, using QoL score as a dependent variable and other factors as 
independent variables found that patients in remission status (r
2
 = 0.436,p-value <0.001), 
patients with high educational levels (r
2
 =0.035, p-value=0.009) and those using 
Azathioprine (r
2
 =0.017, p-value=0.034) were independently associated with high QoL. The 
factors significantly associated with QoL according to stepwise regression analyses are 
summarized in Table 4.8. 
Stepwise regression analysis explained 54.1% of variation in QoL with these independent 
variables (disease status, level of education, using corticosteroid, Antibiotics and  
Azathioprine. The factor that affects IBDQ the most is disease status where it interprets 
43.6% of the variation in the IBDQ. Furthermore it is the factor that affects bowel, systemic, 
social and emotional domain the most where it interprets 41.1%, 41.2%, 37.7% and 40.7% of 
the variation in each domain respectively. 
As a change in disease activity from remission to relapse statues was significantly negatively 
associated with change in QoL score. Relapse results in a decrease in IBDQ and all domains 
score. Highly educational level considered a positive predictor for IBDQ scores, bowel, 
emotional and social domains and using Azathioprine (Imuran
®
) drug also considered a 
positive predictor for IBDQ scores and social domain. While taking corticosteroid medication 
was negatively associated with IBDQ scores and the four domains (social, emotional, bowel 
and systematic domains) as shown in Table 4.8. 
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Table4.8: Stepwise regression models testing for the predictors of QoL of IBD patients in 
Palestine (2017). 
 
Model 
Variable  
R 
R 
Square 
R 
Square 
Change 
B Sig. 
Bowel domain 
Disease activity status 
 
0.641 0.411 0.411 -0.462 
0.000
* 
Level of education 
 
0.673 0.453 0.042 0.209 
0.002
* 
Corticosteroid Drug 
 
0.700 0.490 0.037 -0.617 
0.003
* 
Disease duration 
 
0.716 0.513 0.024 -0.370 
0.015
* 
Stress related condition 
 
0.728 0.530 0.017 -0.353 
0.035
* 
Systematic 
domain 
Disease activity status 
 
0.642 0.412 0.412 -0.432 0.000* 
Corticosteroid Drug 
 
0.678 0.459 0.047 -0.739 0.005* 
Adalimumab Drug 
 
0.696 0.484 0.025 -0.502 0.008* 
Social domain 
Disease activity status 
 
0s.614 0.377 0.377 -0.443 0.000* 
Azathioprine Drug 
 
0.640 0.409 0.032 0.459 0.009* 
Corticosteroid Drug 
 
0.666 0.444 0.034 -0.681 0.006* 
Level Of Education 0.683 0.466 
0.023 
 
0.179 0.022* 
Antibiotics 0.696 0.485 
0.019 
 
-0.258 0.034* 
Emotional domain 
Disease activity status 
 
0.638 0.407 0.407 -0.426 0.000* 
Level of education 
 
0.666 0.443 0.036 0.198 0.005* 
5-ASA 
 
0.688 0.474 0.030 0.312 0.008* 
Corticosteroid Drug 
 
0.703 0.495 0.021 -0.461 0.023* 
Adalimumab Drug 
 
0.716 0.512 0.017 -0.350 0.036* 
IBDQ 
Disease activity status 
 
0.660 0.436 
0.436 
 
-0.347 0.000* 
Level of education 
 
0.686 0.471 
0.035 
 
0.148 0.009* 
Corticosteroid Drug 
 
0.709 0.503 
0.031 
 
-0.460 0.006* 
Antibiotics 0.724 0.525 0.022 -0.184 0.022* 
Azathioprine Drug 
 
0.736 0.541 
0.017 
 
0.276 0.034* 
*P value ≤0.05                           
R: regression coefficient, B: standardized coefficient, Sig.: significance  
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5. Discussion 
This study is the first of its type in Palestine to assess IBD patients QoL, demographic and 
clinical characteristics of the patients, their medication adherence and factors affecting their 
health related QoL. 
This study provides health care professionals with information concerning IBD patients QoL 
in Palestine, and to assess the extent to which different socio-demographic factors (age, 
gender, etc.), clinical variables and medication adherence impact on the QoL of IBD patients. 
Recently the importance of QoL studies has been largely recognized especially for chronic 
diseases.  IBD affects not only patients’ well-being, but also social implications which was 
largely affected either by disease itself, its complication, need for hospitalization, frequent 
physician visits and the side effects of treatment(Casellas, López-Vivancos et al. 2002).   
5.1Assessment of QoL in IBD patients  
In our study, IBDQ instrument was applied to measure IBD patients QoL. IBDQ was also 
used to assess QoL among IBD patients in different countries (de Boer, Wijker et al. 1995, 
Han, McColl et al. 1998, Pallis, Vlachonikolis et al. 2002, Alowais, Alferayan et al. 2016) . 
The total score for IBDQ of IBD patients was (150.72 ± 30.4), indicating that our population 
had a relatively lower QoL than other populations such as Netherlands, England and Grecian, 
Saudi Arabia. Our population total score was lower than Han et al,Athansions G et al. and 
Alowais et al. as they scored (173.7 ± 33.1),(178.1 ± 36.9) and (160.3 ± 42.7) respectively  
and was higher compared to De Boer et al study (N=271) which had a total  QoL scores 
(119.1 ± 22.0) (de Boer, Wijker et al. 1995, Han, McColl et al. 1998, Pallis, Vlachonikolis et 
al. 2002, Alowais, Alferayan et al. 2016). 
These variations in QoL may be due to several factors, firstly: the differences in methodology 
such as different patient population .Secondly: differences in cultural understanding, attitudes 
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towards the disease aspects and the degree of social support between different populations 
also seem as factor. Thirdly: ethnicity and genetic factors may contribute to disease behavior 
and patients response to treatment thus affecting patients QoL. And finally, these differences 
might be due to inclusion of patients with severe symptoms who seek the medical advice, 
generally patients in developing countries do not seek medical advice until debilitating 
symptoms or complications appeared, so a delay in treatment that results in a reduction in 
patient’s QoL occur. 
Comparison between IBDQ dimensions, emotional and bowel dimensions in our sample 
(54.48±13.56) and (46.1±12.2); respectively were more disturbed than systemic and social 
once (23.7±6.45) (24.75±6.6) respectively); this indicated that patients with IBD suffer from 
significant psychological stress that affects patients QoL due to their chronic disease and 
symptoms. 
Social domain had a higher score in our population and this is similar to a study conducted by 
Horváth et al. in 2012, that used SF-36 questionnaire to measure QoL in their sample, they  
showed that QoL impairment are less in social functions than other domains (Horváth, Farkas 
et al. 2012). The data also differs from studies that showed IBD had more impact on patients’ 
social and systemic symptoms when compared to the emotional and bowel symptoms (de 
Boer, Wijker et al. 1995, Han, McColl et al. 1998, Pallis, Vlachonikolis et al. 2002). 
Social domain is the least affected in our sample and this finding could be explained by 
differences in socio-demographic characteristics of the participants as a high proportion of 
our sample (52.3%) were of employed category and 16.7% were students either in a 
university or a secondary school and almost both categories have daily working activity 
which enhances the social communication of them. 
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5.2Association between IBD patients QoL and socio-demographic and clinical factors 
According to relationships between socio-demographic factors and patients QoL, gender 
didn’t affect any QoL domain in our population, this result is  in agreement with Zahn et al. 
study  that concluded demographic parameters did not significantly affect IBDQ scores 
(Zahn, Hinz et al. 2006).While several literatures indicated that female gender was associated 
with a lower QoL than male (Hjortswang, Järnerot et al. 2003, Moradkhani, Beckman et al. 
2013). This is maybe due to differences in socio-demographic and clinical characteristics of 
the both genders in the study. 
The importance of age variable in patients QoL have been indicated in several studies (Badia, 
Fernandez et al. 1995, Han, James et al. 1999, Hjortswang, Järnerot et al. 2003). In this study, 
similarly to other reports (Graff, Walker et al. 2006, Haapamäki, Turunen et al. 2009, Moser 
2009) age variable was not found to affect QoL in IBD patients, this result also in line with 
Moradkhani et al. study conclusions (Moradkhani, Beckman et al. 2013). While increasing 
age increases the emotional domain score in our study and this may be related to increasing 
patient’s ability to cope with the disease, relapse symptoms, or complications of therapy as 
the age increases. 
Disease duration, treatment options and prescribing medication also had no impact on 
patient’s health related QoL. No statistical difference due to their disease duration either less 
than five years or more, this is in agreement with Kalafateli et al. who didn’t find  differences 
in patients with either short or long history of IBD regarding their QoL (Kalafateli, Triantos 
et al. 2013) and comparable with Jäghult et al. study as patients with short disease duration 
had lower QoL scores compared with patients with long disease duration (Jäghult, Saboonchi 
et al. 2011). 
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Imuran
® 
(Azathioprine) and Pentasa
® 
( 5-ASA) were the two most commonly used 
medication by Palestinian patient population (72.7% and 68.2% respectively). Prednisone 
was prescribed to 18.6% of the sample; this is consistent with general practice. Prednisone 
can be used during flare up and two biological may be utilized: Humira
®
 and 
Remicade
®
(Mowat, Cole et al. 2011, Waljee, Wiitala et al. 2016) . 
The information concerning the impact of different treatments on QoL in previous studies 
was conflicting (Bernklev, Jahnsen et al. 2005, Haapamäki, Turunen et al. 2009, 
Romberg‐Camps, Bol et al. 2010). In this study,  no significant difference was found among 
users and non-users of corticosteroids, 5-ASA, and immunosuppressive therapy except for 
Adalimumab (p-value=0.047). Although, this may be due to the small number of patients 
included.  
Despite our data showed no significant association between IBDQ scores and method of 
treatment ,Blanco et al., 2005 study showed that patients undergoing a surgery during their 
disease life had a lower IBDQ scores in compared to those who received medical treatment 
only and the difference was significant (Blanco, Moreno-Jimenez et al. 2005). 
Smoking is a well-known factor in the clinical course of IBD. However, the influence of 
cigarette smoking on QoL is less well known. Our data showed no significant difference 
between smokers and non-smokers regarding QoL this result supports what Casellas et al. 
concluded in 354 patients with IBD were interviewed  in Spain (Casellas, Lopez-Vivancos et 
al. 2002). 
As 68% of our patients had dietary restriction based on patients opinion and this is around the 
percentage reported in a systematic review that approximately 70% of IBD patients are 
known to employ elimination diets to prolong their remission status (Holt, Strauss et al. 
2017). However, no significant association regarding their QoL had been detected. 
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5.3Association between patients QoL and disease activity  
Patients in active disease status (Relapse) had statistically lower IBDQ scores than those in 
remission (Table 4.5). This is conducted in several literatures (Casellas, López-Vivancos et 
al. 2001, Mnif, Mzid et al. 2010, Romberg‐Camps, Bol et al. 2010, Zhou, Ren et al. 2010). As 
disease activity is one of the most important independent variable responsible for IBDQ 
scores and patients QoL (Larsson, Lööf et al. 2008). This may be due to the active disease 
symptoms in comparable to those in clinical remission who suffers from fewer symptoms and 
less complications (Hjortswang, Ström et al. 1998).  Relapse symptoms such as GI and extra 
intestinal symptoms and their complications have a large effect on patient’s health, worries 
and increase anxiety, depression and reducing patients QoL (Graff, Walker et al. 2006). 
5.4 Association between patients QoL and type of disease 
In this study we didn’t find  significant difference regarding QoL between CD and UC  
patients,  this finding  is in line with other studies where diagnosis (CD vs. UC) was not 
related to bowel symptoms, emotional function, social impairment and systematic 
impairment, suggesting that diagnosis is not a key determinant of QoL in IBD (Badia, 
Fernandez et al. 1995, Mussell, Böcker et al. 2004, Blanco, Moreno-Jimenez et al. 2005, 
Zhou, Ren et al. 2010) on the other hand several studies indicated that CD patients have more 
impact on patients psychosocial function,  patients well-being, as well as lower QOL scores 
in comparison to UC patients (Drossman, Leserman et al. 1991, Mnif, Mzid et al. 2010, 
Romberg‐Camps, Bol et al. 2010), it may be due to the severity of CD which is variable in 
different areas of the world. 
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5.5 Assessment of medication adherence and its relationship to patients QoL 
This study is the first of its type in Palestine and Arab world that assess medication adherence 
in IBD patients and examined the health related QoL simultaneously in the same population. 
Low medication adherence was reported in about 39.4% of IBD patients, this lies in  the limit 
of non-adherence to oral medications that was reported in Jackson et.al., review (Jackson, 
Clatworthy et al. 2010) ranging from 7% to 72% but higher than what was reported for Asian 
IBD patients  that ranged from  20%to 30% (Kawakami, Tanaka et al. 2013). Also higher 
than study conducted in Italia 2017 (Bucci, Zingone et al. 2017) to assess medication 
adherence in 151 IBD  patients using  MMAS questionnaire and reported  30% of IBD 
patients had low compliance to their medication. 
 
The results of our study showed that medication adherence did not have impact on patients’ 
QoL, this is in line with Horvath et al. study that included a relatively large number of IBD 
patients and didn’t  find any association between medication adherence and patients QoL 
(Horváth, Farkas et al. 2012).Although our results differ from Hommel et al., study 
(Hommel, Davis et al. 2008) as  the relation between medication adherence and QoL in 36 
young people with IBD was significant. However there are some limitations in Hommel et al 
study including the types of the different surgeries, small number of patients (N=36).  
It seems that QoL in IBD patients is mainly influenced by the disease itself; the presence of 
chronic relapsing symptoms that affects patient’s life. 
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5.6 Predictors of IBD patients QoL 
Identify predictors of IBD patients QoL may help to make interventions that improve 
patient’s health and overall management (Moradkhani, Beckman et al. 2013). Several 
literature publications indicate that the most important variable for predicting health related 
QoL is disease activity statues, such as the presence of relapse (Mnif, Mzid et al. 2010, Zhou, 
Ren et al. 2010, Alowais, Alferayan et al. 2016). The present study found that relapse was a 
significant predictor for the systemic, social, bowel and emotional domains, as well as IBDQ. 
Relapse or the active disease resulted in a decrease of QoL scores (Table 4.8). 
Level of education was a significant predictor for bowel, social and IBDQ scores where 
patients with higher education levels led to increase in QoL scores (Table 4.8). Generally, the 
relationship between education and QoL in chronic diseases is well known and presented in 
the literature (Wang, Beyer et al. 2008, Mielck, Reitmeir et al. 2012, Saleem, Hassali et al. 
2014). As Moradkhani et al. concluded that education may improve the way by which 
patients deal with chronic diseases (Moradkhani, Kerwin et al. 2011). Highly educated 
patients have a higher chance to read about their disease, symptoms and learn how to deal 
with frequent relapses so improvement in QoL scores has been detected. Also their 
knowledge makes them less worried and anxious regarding symptoms. This is relevant for 
patients with IBD because depression is considered a one of the good predictors for 
subjective impairment in QoL(Cuntz, Welt et al. 1999) . 
Differences in IBDQ score in patients receiving different medications may be explained by 
differences in disease activity status from relapse to remission. Using Corticosteroid 
medication was negatively associated with patient’s bowel, systematic, emotional and social 
as well as IBDQ score as shown in Table 4.8. As corticosteroids are the core of “rescue” 
therapy for patients who are experiencing a flare(Waljee, Wiitala et al. 2016), the reduction in 
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patients QoL may be related to disease activity status rather than drug itself. However  a 
study conducted by Vivan et al. concluded that patients who were taking prednisone had  
better QoL (Vivan, Santos et al. 2017) although a small number of patients were included in 
their sample (N=58). Azathioprine (Imuran
®
) drug was considered a positive predictor for 
increasing QoL in both social domain and IBDQ scores, and 5-ASA (Pentasa
®
) for emotional 
domain. 5-ASA is highly effective in mild to moderate UC, and can be used in conjugation 
with other therapies in clinical remission of CD. 
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6. Conclusions and Recommendations 
 
6.1 Strengths and limitations 
Major strengths of this study include: This is the first study about health related QoL among 
IBD patients conducted at West Bank in Palestine;specifically in North and South Palestine. 
It provides baseline data about Palestinian IBD patients QoL, their most commonly used 
medications, their medication adherence, also tried to identify a number of significant 
associated factors that should be considered when dealing with IBD patients. This study is the 
first of its type in Palestine and Arab world that assess medication adherence in IBD patients, 
and examined the health related QoL and the adherence simultaneously in the same 
population. Only a few studies examined the impact of medical adherence on QoL in IBD 
patients. The current study measured QoL and medication adherence by using the global 
instruments: MMSA-8 and IBDQ scales. 
Study Limitations 
The study has several limitations, first, it was conducted in only three hospitals in the West 
Bank, Palestine, and thus the results may not be generalized. Second, although a convenience 
sample of patients in hospitals was selected, some positive selection bias is still possible. 
Also, the cross-sectional type of this study may prevent us from developing a good cause 
effect relationship to be identified especially between post-treatment improvement and QoL 
regarding medication. Lastly, gathering study data via patient’s interview may have a 
negative outcome as the researchers can influence participant’s answers, leading to less 
reliable data. 
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6.2 Conclusions  
This study shows a low QoL among Palestinian IBD patients compared to other countries and 
identifies a number of significant associated factors that should be considered when dealing 
with IBD. Results of the study may help healthcare providers to identify patients at risk of 
low QoL especially those in the relapse status and active symptoms. Attention should be 
provided by healthcare givers and strategy makers to increase knowledge about IBD, to 
improve IBD patient’s QoL and to clarify the importance of treatment adherence  .  
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6.3 Recommendations 
Results of this study give an idea about the status of IBD patients QoL in Palestine and 
provide some assessment of their medications, disease activity, medication adherence, and 
the predictors of disease. Our findings also point out some important issues that need to be 
addressed in future, and these include the followings: 
 Population-based studies are needed to investigate the incidence of IBD in Palestine. 
 The use of IBDQ questionnaire should be implemented for regular follow up in the 
clinic to evaluate the response to management 
 Attention should be provided by healthcare providers and strategy makers, doctors 
and health educators to low level QoL. Patients with high risk of low QoL are more 
likely to have relapsed and active symptoms that interfere with daily living. 
 Awareness sessions for IBD patients to clarify the importance of adherence to their 
medication and the type of food recommended or food that needs to be avoided in 
order to maintain remission. 
 Finally, we recommend making periodic studies on larger population and longer 
duration with patients follow up to confirm the findings of this study. 
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ٗافق ػيٚ ٍقبثيخ أٗثزىل  ,ٖٝذف ىزقٌٞٞ  مفبءٓ اىسٞبٓ ىذٛ ٕذافٔ ٗغبٝزٔ ىٜ ٍِ قجو اىشخض اىَقبثو ٗاىزٛ أ
ٕٜٗ  5046387950رغٌْٞ اعَبػٞو عَٞشاد اىزٜ رسَو ٕبرف سقٌ ٍِ ٝدشٛ اىجسث ٕٜٗ اىطبىجٔ  
اىجسث اىٚ قٞبط ٍذٙ  ٖٗٝذف ثزخظض ػيً٘ طٞذلاّٞخ  ردشٛ ثسث ىَششٗع اىزخشج ٍِ خبٍؼٔ اىقذط
رشرجؾ  خ مفبءٓ اىسٞبٓ ىذٛ ٗىذٙ اىَشػٚ اىزِٝ ٝؼبُّ٘ ٍِ ّفظ اىَشع ٍٗقبسّزٖب ثؼ٘اٍو ٍخزيف
ُ ٍؼيٍ٘برٜ أػيٌ أٗطفٖب ىٜ .ٗ ٜ رٌ ادسك اُ اىَقبثئ اىزبثؼٔ ىٖزا اىجسث عزدشٙ ثبىطشٝقٔ اىزثبىَشع . 
ٛ ٗقذ أّغست ٍِ اىَقبثيخ فٜ أٗ أٍلازظبد ٝخ أغٞش أُ أعزطٞغ أّٔ ثنبٍو زشٝزٜ أُ ٗعزجقٚ ؽٜ اىنزَب
  ..
 
 اىز٘قٞغ ..................................
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 اﻋذاد انطبنجخ : رسىٕم اسمبﻋٕم اثشإٌم سمٕشاد 
  انذﻛزُس الاسزشبسْ قصٓ ﻋجذي س حسٕه انحلاق َ, انذﻛزُانذﻛزُس ﻣبٌش انخضُس: ثبششاف 
 
 انمهخص 
ىيغبٝخ ىزقٌٞٞ  ٌٍٖ أٍش ٕ٘ قٞبط خ٘دح زٞبح اىَشٝغ اىَظبة ثَشع ٍِ الأٍشاع اىَضٍْخ:  انمﻘذﻣً
رأثٞش مجٞش ػيٚ خ٘دح زٞبح اىَشػٚ. ٗقذ  رٍٗشع الأٍؼبء الاىزٖبثٜ ٝؼذ  .ّزبئح اىَشع ٗرأثٞش رذاخلارٔ
. ٖزا اىَشعقخ أُ ّشبؽ اىَشع ٕ٘ ٍؤشش ٌٍٖ ىد٘دٓ زٞبح اىَشػٚ اىَظبثِٞ ثاقزشزذ اىذساعبد اىغبث
 د٘دح زٞبح ٍشػٚث ثبلأدٗٝخفٜ خَٞغ أّسبء اىؼبىٌ رجِٞ ػلاقخ الاىزضاً ٍِ اىذساعبد  ْٕبك ػذد ٍسذٗد
. ىزىل رٌ إخشاء ٕزٓ اىذساعخ ىفسض الاسرجبؽ ثِٞ ّشبؽ اىَشع  الاىزٖبة الاٍؼبئٜ ّٗزبئدٖب ٍزؼبسثخ 
الأٍؼبء فٜ فيغطِٞ . أٝؼب ، ٕذفذ اىزٖبة لاىزضاً ثبى٘طفخ اىذٗائٞخ  ٗأثشَٕب ػيٚ خ٘دح زٞبح ٍشػٚ ا,
ٕزٓ اىذساعخ ىزسذٝذ خ٘دح زٞبح اىَشػٚ , الاىزضاً اىذٗائٜ ىذٌٖٝ ٗأٝؼب ىنشف اىؼ٘اٍو اىَشرجطخ ثد٘دح 
 .ٗرؤثش ػيٖٞب زٞبرٌٖ
فٜ ٍغزشفٚ  8102إىٚ شجبؽ / فجشاٝش  7102دساعخ ٍغزؼشػخ ٍِ رَ٘ص / ٝ٘ىٞ٘  أخشٝذ: الأسبنٕت
اىسنٍٜ٘، اىخيٞو، ٗفٜ ٍغزشفٚ اىذمز٘س خيٞو عيَٞبُ ،  ػبىٞخ خبٍؼخ اىْدبذ اى٘ؽْٞخ، ّبثيظ، ٍغزشفٚ 
 ٍشػٚ اىزٖبة الأٍؼبء اىزقشزٜ اعزجٞبٍُخظظخ ىٖزا اىَشع ٕٜٗ خِْٞ ، فيغطِٞ. رٌ اعزخذاً أداح 
ٍ٘سعنٜ اىَؼذه  ثبعزخذاً ٍقٞبط ثبلأدٗٝخ الاىزضاً ٍذٙ . رٌ قٞبط خ٘دح زٞبرٌٖ ) ىذساعخ QDBI(
). ٗقذ رٌ رسيٞو اىْزبئح ثبعزخذاً ثشّبٍح اىسضٍخ الإزظبئٞخ ىيؼيً٘ 8-SAMM( ىلاىزضاً ثبىذٗاء 
خ٘دح . رٌ إخشاء رسيٞو الاّسذاس اىخطٜ اىَزؼذد ىزسذٝذ إٌٔ اىَزغٞشاد اىَزؼيقخ ثـ ))SSPSالاخزَبػٞخ 
 .زٞبح ٕؤلاء اىَشػٚ
 .٪ ٍِ اىزم٘س 3.85شبسك ٍئخ ٗاثْبُ ٗثلاثُ٘ ٍشٝؼب فٜ ٕزٓ اىذساعخ. ٍِ ثٌْٖٞ ز٘اىٜ  ئح:انىزب
 18عْخ.  07-81ثِٞ أػَبسٌٕ رشاٗزذ  ٗ عْخ 31±  43 ٍِ شبسم٘ا ثبىذساعخ ز٘اىٜ ٍز٘عؾ أػَبس
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 ٍقٞبطثبعزخذاً .ثبىذساعخ مبُ ٍشػٌٖ ّشؾ خلاه اىغزخ شٖ٘س اىَبػٞخ ٪) 4.16(ٌٍْٖ ٍشبسك 
خ٘دح . ٍز٘عؾ ىذٌٖٝ اىزضاً ٍزذّٜ ىلأدٗٝخ ٍِ اىَشبسمِٞ ٪ 4.93مبُ ز٘اىٜ، اىَؼذه ىلاىزضاًٍ٘سعنٜ 
اىْبزٞخ  مبّذ دسخبد. 97.051ٍشػٚ اىزٖبة الأٍؼبء اىزقشزٜ عدو  اعزجٞبُزٞبح اىَشػٚ ثبعزخذاً 
ذّب أُ ّشبؽ ٗٗخالأخشٙ.  ٗأػشاع اىزٖبة الأٍؼبء َٕب الأمثش رأثشا ثبىَقبسّخ ٍغ اىْ٘ازٜ ,اىؼبؽفٞخ
ىٌ رنِ ْٕبىل ػلاقخ ثِٞ ). 100.0<Pقَٞخ(ثد٘دح زٞبح اىَشػٚ اىؼبٍو اىشئٞغٜ اىَشرجؾ اىَشع ٕ٘ 
أٛ ّبزٞخ ٍِ ّ٘ازٜ ػيٚ  (ّ٘ع اىَشع )ىٌ ٝؤثش اىزشخٞض ٍذٙ الاىزضاً ثبىذٗاء ٗخ٘دح زٞبح اىَشٝغ .
 = 2r, (يخ شفبء ىيَشع ٍشز. مشف رسيٞو اىَخبؽش أُ اىَشػٚ اىزِٝ ٝؼبُّ٘ ٍِ خ٘دح زٞبح اىَشٝغ
)، 430.0=  Pقَٞخ530.0= 2r ,( رؼيَٜٞ ػبىٜ ٍغز٘ٙ)، ٗاىَشػٚ اىزِٝ ىذٌٖٝ 100.0<Pقَٞخ 634.0
اسرجط٘ا ٗثشنو ( 900.0= P قَٞخ,)710.0= 2r=  P قَٞخenirpoihtazAدٗاء ٗاىزِٝ ٝغزخذٍُ٘ 
 ٍغزقو ثد٘دح زٞبح أفؼو.
اىَشػٚ اىفيغطِْٞٞٞ اىَظبثِٞ ثَشع اىزٖبة  ٕزٓ اىذساعخ رؼشع اّخفبع خ٘دح زٞبح:سزىزبجالا
الأٍؼبء ثبىَقبسّخ ٍغ اىذٗه الأخشٙ . ٗرسذد  ػذًدا ٍِ اىؼ٘اٍو راد اىظيخ اىٖبٍخ اىزٜ ٝدت أخزٕب فٜ 
ػِٞ  الاػزجبس ػْذ اىزؼبٍو ٍغ ٍشع اىزٖبة الاٍؼبء.ّزبئح ٕزٓ اىذساعخ قذ رغبػذ ٍقذٍٜ اىشػبٝخ اىظسٞخ 
خطش اّخفبع خ٘دح اىسٞبح ٗلا عَٞب اىزِٝ ٌٕ فٜ زبىخ اّزنبعخ أٗ أػشاع ىزسذٝذ اىَشػٚ اىَؼشػِٞ ى
ّشطخ .ٝدت ر٘فٞش الإزَبً ٍِ قجو ٍقذٍٜ اىشػبٝخ اىظسٞخ ٗطبّؼٜ الاعزشارٞدٞخ ىضٝبدح اىَؼشفخ ز٘ه 
    ٍشع اىزٖبة الأٍؼبء ،ٗىزسغِٞ خ٘دح زٞبح اىَشٝغ ٗىز٘ػٞر إَٔٞخ الاىزضاً اىذٗائٜ ىذٙ اىَشػٚ .
 
 
